What if a smartphone could detect your patients’ risk of developing a chronic condition such as type 2 diabetes, heart disease or stroke? What if patients could use a smartphone app to initiate a scan that provided direct feedback on a suspicious lesion on their skin? Through an easy-to-use app, suppose your patients could measure […]

Big developers tend to dominate the vast oncology meetings and this year’s Esmo was no exception. Astrazeneca, with a plenary spot for Enhertu and several well-received presentations on other projects, was the dominant big pharma name. Among the smaller biotechs a couple of winners stand out, according to Evaluate Vantage’s analysis of share price moves over the […]

Imfinzi is the standard of care for post-chemo stage III non-small cell lung cancer, but rivals have been snapping at its heels for some time. Data presented at Esmo last week might give Imfinzi a new edge in this setting, thanks to combination approaches. An interim analysis of the mid-stage Coast trial showed that adding Astra’s own […]